Blood test versus a tumor biopsy: Which reveals more gene mutations in the diagnostics and treatment of gastrointestinal cancer? New research from Dana-Farber Cancer Institute in Boston points very much to the former.
In a small study mounted at the University of Pennsylvania, a novel combination approach using a personalized therapeutic vaccine made from dendritic cells primed with a patient's tumor cells was successfully used to fight advanced ovarian cancer.
Academia is increasingly realizing the medical and financial possibilities that building persona lized medicine programs can bring. Case in point: The Perelman School of Medicine at the University of Pennsylvania this year has unveiled the Center for Personalized Diagnostics, a joint initiative from the school's department of Pathology and Laboratory medicine and the Abramson Cancer Center.
Analysts predict enormous gains in the nanotechnology drug delivery market for the next three years, according to a new report. But the good news comes with a hovering rain cloud, as safety concerns regarding nanomedicines may dampen a bright future.
A new genomics upstart has taken flight to create a new way of mobilizing personal DNA data. Miinome aims to offer a unique personal genetic marketplace, serving as a broker between peoples' genetic info and buyers of the data.
The U.K.'s National Health Service is propelling its diagnostic offerings deeper into the realm of personalized medicine. It will offer a new test that spots mutations in 46 different cancer cell genes in order to gauge how a patient will respond to treatment.
Scientists at the University of Nottingham in the U.K. are developing a quick blood test for early-stage Alzheimer's. The goal, according to a BBC story on the finding, is a diagnostic that would enable earlier intervention, as well as a personalized drug treatment.
Covance is stepping up its personalized medicine services, teaming up with the biomarker-focused M2Gen to better identify ideal patients for oncology drug trials.
Six months after emerging from stealth mode, North Carolina startup GeneCentric is pursuing $2 million in new funding to support the rollout of a targeted lung cancer molecular diagnostic test.
As the need for personalized medicine grows, researchers have been searching for a way to tailor cancer treatments to individuals.